Hospital
South Broward Hospital District
South Broward Hospital District was paid $14.27M by Medicaid between Jan 2018 and Dec 2024, across 202 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoSOUTH BROWARD HOSPITAL DISTRICT
MIRAMAR, FL 33029
MIRAMAR, FL 33029
33aNPI1326021197assigned 11/25/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.27M
24GClaims507,151
24DCodes billed202
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#32 of 163
Median peer was paid$4.77M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,531 | $466K | |
| 2019 | 113,708 | $2.45M | |
| 2020 | 72,550 | $1.41M | |
| 2021 | 93,866 | $2.57M | |
| 2022 | 104,995 | $3.43M | |
| 2023 | 57,964 | $2.60M | |
| 2024incomplete | 22,537 | $1.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 36,087 | 33,036 | $3.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 29,642 | 25,315 | $2.38M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 16,641 | 15,510 | $1.54M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 9,913 | 2,143 | $526K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.4% | 5,691 | 1,252 | $479K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 2,868 | 2,386 | $440K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.6% | 5,097 | 1,102 | $368K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 5,316 | 4,522 | $348K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.2% | 3,776 | 3,417 | $319K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 3,460 | 2,772 | $304K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,674 | 1,384 | $213K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 3,783 | 3,040 | $213K |
190 more codes
| 36415 | Collection of venous blood by venipuncture | 1.3% | 27,352 | $179K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 4,521 | $170K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 6,590 | $161K |
| 80053 | Comprehensive metabolic panel | <1% | 12,278 | $142K |
| G0378 | Hospital observation service, per hour | <1% | 9,400 | $137K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,991 | $136K |
| 76641 | <1% | 1,886 | $134K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,127 | $107K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,888 | $99K |
| 87088 | <1% | 6,825 | $97K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,523 | $89K |
| 84702 | <1% | 12,726 | $85K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,666 | $83K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,459 | $77K |
| 85027 | <1% | 3,402 | $76K | |
| 87631 | <1% | 1,037 | $70K | |
| 86850 | <1% | 3,523 | $67K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 388 | $62K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,620 | $62K |
| 87486 | <1% | 2,606 | $60K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 541 | $60K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,127 | $59K |
| 86900 | <1% | 4,479 | $59K | |
| 97162 | <1% | 538 | $58K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,885 | $56K |
| 76770 | <1% | 853 | $54K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,820 | $51K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 493 | $45K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,112 | $40K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 574 | $37K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,569 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,945 | $36K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 25 | $36K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,580 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,479 | $31K |
| 96112 | <1% | 111 | $31K | |
| 93976 | <1% | 930 | $29K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 41 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 627 | $27K |
| 81001 | <1% | 14,159 | $26K | |
| 84484 | <1% | 7,563 | $26K | |
| 88307 | <1% | 438 | $25K | |
| 73610 | <1% | 517 | $24K | |
| 58662 | <1% | 87 | $24K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 169 | $23K |
| 82962 | <1% | 4,908 | $21K | |
| 81003 | <1% | 5,803 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,094 | $20K |
| 73562 | <1% | 788 | $18K | |
| 82731 | <1% | 199 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,166 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,708 | $16K |
| 76801 | <1% | 1,895 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 603 | $16K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 956 | $15K |
| 81025 | <1% | 1,923 | $15K | |
| 76882 | <1% | 267 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,172 | $14K |
| 77072 | <1% | 398 | $13K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 167 | $12K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 130 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 732 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 977 | $11K |
| 73630 | <1% | 408 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,646 | $10K |
| 87186 | <1% | 1,178 | $10K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 72 | $10K |
| 87040 | <1% | 3,565 | $9K | |
| 74019 | <1% | 844 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,955 | $8K |
| 87581 | <1% | 2,609 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,004 | $8K |
| 86140 | <1% | 2,306 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,944 | $7K |
| 84112 | <1% | 274 | $7K | |
| 85610 | <1% | 6,673 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,303 | $7K |
| 74021 | <1% | 296 | $7K | |
| 80061 | Lipid panel | <1% | 1,826 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,090 | $6K |
| 73130 | <1% | 119 | $6K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 51 | $6K |
| 83690 | <1% | 5,256 | $5K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 802 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,725 | $5K |
| 80076 | <1% | 2,425 | $5K | |
| 85730 | <1% | 4,568 | $5K | |
| 93971 | <1% | 469 | $5K | |
| 59025 | Fetal non-stress test | <1% | 351 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,935 | $5K |
| 83615 | <1% | 1,022 | $5K | |
| 77062 | <1% | 390 | $4K | |
| 73110 | <1% | 176 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,466 | $4K |
| 97161 | <1% | 75 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,219 | $4K |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 5,100 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 120 | $4K |
| 85379 | <1% | 1,244 | $4K | |
| 73030 | <1% | 208 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,651 | $3K |
| 00840 | <1% | 720 | $3K | |
| 87077 | <1% | 1,275 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,235 | $3K |
| 93970 | <1% | 89 | $3K | |
| 73140 | <1% | 82 | $3K | |
| 87210 | <1% | 747 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,405 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,173 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,426 | $2K |
| 36416 | <1% | 235 | $2K | |
| 86901 | <1% | 4,655 | $2K | |
| 74018 | <1% | 239 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 206 | $2K |
| 92523 | <1% | 12 | $2K | |
| 82248 | <1% | 1,473 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,003 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 949 | $2K |
| 87507 | <1% | 189 | $2K | |
| 83880 | <1% | 220 | $1K | |
| 73590 | <1% | 13 | $1K | |
| 72141 | <1% | 17 | $1K | |
| 85384 | <1% | 667 | $1K | |
| 88304 | <1% | 74 | $1K | |
| 71250 | <1% | 130 | $1K | |
| 83605 | <1% | 1,778 | $1K | |
| 83735 | <1% | 1,005 | $1K | |
| 82247 | <1% | 348 | $853.23 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 45 | $851.42 |
| 77080 | <1% | 73 | $823.44 | |
| 76536 | <1% | 17 | $704.55 | |
| 82550 | <1% | 315 | $674.79 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 893 | $658.90 |
| 73080 | <1% | 12 | $601.70 | |
| 84439 | <1% | 619 | $577.55 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 54 | $573.15 |
| 82570 | <1% | 468 | $482.17 | |
| 88342 | <1% | 148 | $480.93 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 29 | $480.93 |
| 70544 | <1% | 15 | $477.44 | |
| 85045 | <1% | 204 | $475.37 | |
| 84156 | <1% | 302 | $472.35 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 994 | $460.66 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 53 | $419.74 |
| 76881 | <1% | 14 | $406.66 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 31 | $400.34 |
| 82607 | <1% | 29 | $371.53 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 120 | $360.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 14 | $358.60 |
| 29515 | <1% | 45 | $280.72 | |
| 85651 | <1% | 1,232 | $277.93 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,882 | $276.21 |
| 72100 | <1% | 117 | $263.73 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,000 | $188.20 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 587 | $171.94 |
| 72040 | <1% | 18 | $170.11 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 96 | $166.94 |
| 87081 | <1% | 228 | $142.04 | |
| 84550 | <1% | 875 | $125.89 | |
| 76870 | <1% | 42 | $119.83 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 215 | $118.21 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 175 | $114.23 |
| 87070 | <1% | 79 | $72.42 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 68 | $68.10 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 13 | $65.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 12 | $65.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 46 | $51.58 |
| 51701 | <1% | 914 | $48.61 | |
| 82728 | <1% | 34 | $37.42 | |
| 87503 | <1% | 80 | $29.22 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 611 | $24.59 |
| 29125 | <1% | 64 | $21.63 | |
| 84480 | <1% | 14 | $21.13 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 909 | $14.08 |
| 82272 | <1% | 35 | $3.09 | |
| 87205 | <1% | 49 | $2.61 | |
| 84100 | <1% | 30 | $1.56 | |
| 12001 | 0% | 13 | $0.00 | |
| 96376 | 0% | 115 | $0.00 | |
| 94010 | 0% | 34 | $0.00 | |
| 86308 | 0% | 27 | $0.00 | |
| 83550 | 0% | 25 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 14 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 561 | $0.00 |
| 12011 | 0% | 108 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 212 | $0.00 |
| 90715 | 0% | 15 | $0.00 | |
| 83540 | 0% | 43 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 15 | $0.00 |
| 88302 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMELISSA, BURNS (DIRECTOR)